Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 13,266 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Adult Disease Clear all

Conditions: Depressive Disorder, Major
Interventions: LY2216684, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 21 more

Conditions: Traumatic Brain Injury, Memory Deficits
Interventions: Donepezil, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 4
States / cities: Indianapolis, Indiana • Charlestown, Massachusetts • Elkins Park, Pennsylvania + 1 more

Conditions: Type2diabetes, Mild Cognitive Impairment, Age-related Cognitive Decline
Interventions: Progressive Exercise Program (12 Weeks); Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 55 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions: Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone; Drug
Lead sponsor: Julio Barredo, MD; Other
Eligibility: 16 Years to 39 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Epilepsy
Interventions: TPM XR; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Sacramento, California • Loxahatchee Groves, Florida • Miami, Florida + 7 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: pyroxamide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Diamond Blackfan Anemia
Interventions: Sotatercept, Sotatercept with prednisone boost; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Fever, Critical Illness
Interventions: Acetaminophen, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Neurofibromatosis Type II
Interventions: Everolimus (RAD001) , Afinitor®; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 3 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Safety and Pharmacokinetics of Intravenous Baclofen
Interventions: Intravenous baclofen; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Dental Caries
Interventions: C16G2 Varnish, Placebo Varnish; Drug
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Kalispell, Montana • Bedford, Texas • Irving, Texas

Conditions: Old Age; Debility, Peripheral Neuropathy
Interventions: Protective Arm Balance Response Training; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 45 Years to 88 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non Hodgkin Lymphoma, Solid Tumor
Interventions: SB-4826, Rituximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Budigalimab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Bakersfield, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: COVID-19
Interventions: COVID-HIGIV, Placebo (saline); Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrophy of Vocal Cord, Presbyphonia, Dysphonia, Glottic Insufficiency, Voice Change, Voice Disorder, Adults, Aging, Speech Therapy, Voice Alteration
Interventions: exuberant voice therapy; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 54 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Arcadia, California • Beverly Hills, California • Glendale, California + 1 more

Conditions: Non-Nutritive Sweetener, Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus
Interventions: Cherry Sports Drink; Dietary Supplement
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 15 Years to 24 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: cixutumumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Months to 30 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 93
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more

Conditions: Rheumatoid Arthritis
Interventions: AD 452; Drug
Lead sponsor: Sosei; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 10
States / cities: Clearwater, Florida • Fort Lauderdale, Florida • Ocala, Florida + 7 more

Conditions: Asthma
Interventions: Rhinovirus; Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 40 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy
Interventions: PF-04634817; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cystic Fibrosis
Interventions: Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge, Olfactory Function Testing, Survey Completion; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Adult Solid Tumor
Interventions: CANscript; Diagnostic Test
Lead sponsor: Mitra RxDx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Gilbert, Arizona • Aurora, Colorado • Norwich, Connecticut + 23 more

Conditions: Major Depressive Disorder
Interventions: SEP-363856, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 53
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more

Search by objective public record fields.

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Multicenter Evaluation of Memory Remediation After TBI With Donepezil

Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Pyroxamide in Treating Patients With Advanced Cancer

Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia

Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers

A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects

Protective Arm Balance Responses

SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

PhoRTE® Therapy Efficacy: In-Person Versus Telehealth

Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D)

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.

Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic

A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects

Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder